BioSpace News Archive

Alligator Bioscience (Nasdaq Stockholm: ATORX), announces that the company today presents additional novel data from the ongoing Phase I clinical trial with the bispecific drug candidate ATOR-1015 developed as tumor-directed therapy for metastatic cancer, which further validates the potential of the drug. The presentation will be held a

Takeda to Present Data from the ICLUSIG ® (ponatinib) Clinical Trial Program that Could Prove Practice-Changing for the Treatment of Chronic-Phase CML – Oral Presentations of the Phase 2 OPTIC Interim Analysis at the American Society of Clinical Oncology (ASCO) and the European Hematology Association (EHA) Annual Meetings – – Findings Support Response-Based Dosing Regimens of ICLUSIG Can Optimize Benefit-Risk Profile in Patients with Resistant / Intol

The treatment for lung infections has conventionally been led by small molecule therapies.

Bacteriophage, also simply known as phages, are bacterial viruses that infect and feed on bacteria to replicate themselves.

Ovation Science Inc., is providing an update to its previous disclosures regarding its DermSafe® hand sanitizer product.

Tetra Bio-Pharma Inc., a bio-pharmaceutical company engaged in cannabinoid-derived drug discovery and development, announces granting of a new patent from the Australian Patent Office for patent application number 2016268872.

RGENIX, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, announced today it is presenting data showing clinical activity in patients with advanced colorectal (CRC) tumors from a clinical trial of RGX-202, a first-in-class small molecule that inhibits a novel canc

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced new preclinical data for SY-5609, its highly selective and potent oral inhibitor of cyclin-dependent kinase 7 (CDK7). The data show that SY-5609 inhibits tumor growth, includi